Roger J. Bedimo, MD
Chief, Infectious Diseases Section
Veterans Affairs (VA) North Texas Health Care System
Professor of Medicine
UT Southwestern Medical Center
Dallas, Texas

Target Audience

The educational design of this activity addresses the needs of infectious disease specialists, internal medicine physicians, transplant specialists, oncologists, pharmacists, and other clinicians involved in managing patients who are at heightened risk for poor COVID-19 outcomes.

Educational Objectives 

After completing this activity, the participant should be better able to:

  • Create proactive plans with patients, other clinicians, and health care systems to ensure prompt and equitable use of COVID-19 therapies

Program Description

The efficacy of monoclonal antibodies for treatment and prevention of COVID-19 has been severely impacted by the constant evolution of viral variants and subvariants. The previously used monoclonal antibodies are no longer effective against the currently circulating COVID-19 variants, leaving clinicians awaiting new options that are in the pipeline, especially for immunocompromised patients. In this program, Dr. Roger Bedimo reviews the latest information on the status of COVID-19 in the US, including currently circulating variants and the monoclonal antibodies under investigation for potential use as pre-exposure prophylaxis and treatment.

Physician Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hours of pharmacology).

Disclosures of Relevant Financial Relationships

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global Education Group are required to disclose all financial relationships with any ineligible company within the past 24 months to Global Education Group.  All financial relationships reported are identified as relevant and mitigated by Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global Education Group to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated.

Roger J. Bedimo, MD: Consultant Fees: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co, Inc., ViiV Healthcare, Shionogi Inc., Theratechnologies Inc.

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 100% on the posttest and complete the program evaluation.

Global Education Group Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Begin Activity
available resources
linked resources
Suggested Reading
Regional Webinars & Breaking News Updates

What’s the Latest on COVID-19?